EDSA

Edesa Biotech, Inc. [EDSA] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

EDSA Stock Summary

Top 10 Correlated Stocks

EDSA

In the News

EDSA Financial details

Company Rating
-
Market Cap
14.21M
Income
-7.72M
Revenue
-1.12M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
16
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-1.63
Forward P/E
-
PEG
0.8
P/S
-
P/B
1.92
P/C
-
P/FCF
-2.26
Quick Ratio
3.29
Current Ratio
3.53
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.84
EPS next Y
-
EPS next Q
-
EPS this Y
-60%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-4.9%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
575.84%
-
-
-
-
SMA20
66.67%
SMA50
900%
SMA100
400%
Inst Own
-
Inst Trans
-
ROA
-94%
ROE
-98%
ROC
-1.3%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
2.46-8.61
52W High
+97%
52W Low
+688%
RSI
83
Rel Volume
160.05
Avg Volume
13.5K
Volume
2.16M
Perf Week
106.01%
Perf Month
104.94%
Perf Quarter
832.54%
Perf Half Y
499.24%
-
-
-
-
Beta
0.92
-
-
Volatility
3.61%, 2.76%
Prev Close
10.52%
Price
15.76
Change
46.47%

Something similar

Top by Market Cap
VTI
APC.DE
MSF.DE
LLY.DE
LLY.SW
Same Sector
OPHLF
CVRX
CALTX.ST
LUMO
3692.HK
Top Correlated Stocks
CMTV
600703.SS
DCBO
BBW
5262.T
Similar Market Cap
ZKIN
ERWE.DE
PMNT.L
GRC.TO
GLCN

Company Profile

Healthcare Biotechnology
  • Volume Average 13.5K
  • Market Capitalization 14.21M
  • Employee 16
  • CEO Dr. Pardeep Nijhawan FRCPC, M.D.
  • Headquarters Markham,ON,CA
  • IPO Date 2010-06-21
  • Website https://www.edesabiotech.com

Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.